Immunotherapy against invasive mold infections.

Area of Science:

• Mycology
• Immunology
• Hematology

Background:

• Invasive filamentous fungal infections (e.g., Aspergillus, Zygomycetes) lead to severe illness and death in immunocompromised individuals, including those with hematological malignancies and transplant recipients.
• Standard antifungal therapies often yield poor outcomes, highlighting the critical role of immune restoration in treatment success.
• Effective antifungal immunity relies on robust innate phagocytic functions and balanced pro-inflammatory and regulatory adaptive immune responses.

Purpose of the Study:

• To review the role of immunomodulatory approaches as adjunctive treatments for invasive mold infections in immunocompromised patients.
• To evaluate the current clinical evidence supporting the use of cytokines, T lymphocytes, and granulocyte transfusions in managing these serious fungal infections.

Main Methods:

• Literature review of studies investigating immunomodulatory strategies for invasive fungal infections.
• Analysis of in vitro and in vivo data on cytokine therapy, adoptive T cell transfer, and granulocyte transfusions.
• Assessment of current clinical evidence and recommendations for immunomodulatory treatments.

Main Results:

• Immunomodulatory strategies, including cytokine administration, pathogen-specific T lymphocyte transfer, and granulocyte transfusions, have been explored as adjunctive therapies.
• Encouraging in vitro and in vivo data exist for these approaches.
• However, current clinical evidence is insufficient to establish firm recommendations for their use in treating serious mold infections.

Conclusions:

• Immune restoration is crucial for treating invasive fungal infections in immunocompromised patients.
• While several immunomodulatory approaches show potential, robust clinical data is lacking.
• Further clinical trials are necessary to determine the efficacy and safety of immunomodulatory modalities in managing serious mold infections.